bendamustine + bortezomib + prednisone

Bendamustine + bortezomib + prednisone is a three-drug combination regimen used primarily for the treatment of multiple myeloma (MM), including both newly diagnosed and relapsed/refractory cases. Bendamustine is a bifunctional alkylating agent that induces cell death by forming DNA crosslinks, affecting both quiescent and dividing cells. Bortezomib is a proteasome inhibitor that disrupts protein degradation pathways in cancer cells, leading to apoptosis. Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties that also induces apoptosis in certain hematologic malignancies. This combination has demonstrated efficacy as induction therapy for MM patients who are transplant-eligible or ineligible, with studies showing high response rates and manageable toxicity profiles[1][2][4][8].

Other names

bendamustine + bortezomib + prednisoneBVPBPV